Cytokinetics
CYTK
101 hedge funds and large institutions have $323M invested in Cytokinetics in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 29 increasing their positions, 35 reducing their positions, and 9 closing their positions.
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
65.48% more ownership
Funds ownership: 0% → 65.48% (+65%)
32% more capital invested
Capital invested by funds: $246M → $323M (+$77.4M)
11% more funds holding
Funds holding: 91 → 101 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less call options, than puts
Call options by funds: $358K | Put options by funds: $423K
17% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 35
Top Buyers
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.43M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.46M |
| 3 |
Morgan Stanley
New York
|
+$1.72M |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
+$1.48M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.45M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.22M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$1.54M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.22M |
| 5 |
Millennium Management
New York
|
-$1.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HVC
101
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| – | -$918K | -100,000 | Closed |
|
|
HCM
102
Highbridge Capital Management
New York
| – | -$543K | -59,075 | Closed |
|
|
ZIM
103
Zacks Investment Management
Chicago,
Illinois
| – | -$237K | -25,787 | Closed |
|
|
SSA
104
Schonfeld Strategic Advisors
New York
| – | -$184K | -20,000 | Closed |
|
|
RJA
105
Raymond James & Associates
St Petersburg,
Florida
| – | -$105K | -11,450 | Closed |
|
|
DS
106
DRW Securities
Chicago,
Illinois
| – | -$92K | -10,000 | Closed |
|
|
EMG
107
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$92K | -10,000 | Closed |
|
|
PCA
108
Peddock Capital Advisors
Braintree,
Massachusetts
| – | -$2K | -261 | Closed |
|
109
AssetMark Inc
Concord,
California
| – | +$361 | +34 | New |
|
CYTK Hedge Fund Activity: Q4 2016 in Review
101 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2016, worth a combined $323M — up 32% from $246M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CYTK positions and 9 closed out — a net gain of 11 holders — while 29 added to existing stakes and 35 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $7.43M. The largest seller was EcoR1 Capital, cutting an estimated $8.4M.
- 101 institutional investors held Cytokinetics (CYTK) as of Q4 2016, up from 91 in Q3 2016.
- Funds reported $323M of Cytokinetics stock for Q4 2016, up 32% quarter-over-quarter.
- 20 funds opened new Cytokinetics positions in Q4 2016 and 9 closed out, a net change of +11 holders.
- The largest Cytokinetics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $7.43M added.
- The largest Cytokinetics seller in Q4 2016 was EcoR1 Capital, an estimated $8.4M sold.
Based on aggregated 13F filings for Q4 2016.